Prospective, multicenter, randomized, open lable, parallel controlled trial for intravenous injection of bionica pulse insulin for the improvement of respiratory quotient in Chinese diabetic patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027510

Enrollment

Unknown

Registered

2019-11-17

Start date

2012-11-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Treatment group:Receive insulin by pulse intravenous injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed type I or type II diabetes; 2) Aged 18 to 75 years old; 3) Patients with respiratory quotient (RQ) less than 0.8; 4) Patients signing informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnant, nursing or improper contraception; 2) Patients with acute complications; 3) Suffering from serious life-threatening diseases; 4) Patients participating in other clinical studies within three months; 5) Patients who have donated blood within three months; 6) Patients with periodic paralysis; 7) Patients taking drugs that may cause hypokalemia; 8) There may be any situation that increases the risk of the patient or interferes with the clinical trial, and the patient is not suitable for the study.

Design outcomes

Primary

Measure	Time frame
Respiratory quotient;	—

Secondary

Measure	Time frame
Glucose;HbA1c;Operation convenience;Diabetes impact scale;TCHO;Microalbuminuria;Triglyceride;	—

Countries

China

Contacts

Public ContactGuo Xiaohui

Peking University First Hospital

bdyyguoxiaohui@sina.com+86 13601337277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026